Host pathways controlling susceptibility and resistance to Mtb.  We have identified chemical compounds that super-activate macrophages in vitro and improve control of experimental Mtb infections in mice. We are working out their targets in the hopes of contributing to host-directed therapy as an adjunct to antimicrobial therapy of tuberculosis. Additional approaches to identifying targets for host-directed therapy include a CRISPR-Cas9-mediated loss-of-function genetic screen and use of combinatorial phage-based antibody libraries in loss- and gain-of-function screens.